Letter

Design, Synthesis, and X-ray of Selenides as New Class of Agents for Prevention of Diabetic Cerebrovascular Pathology

Andrea Angeli,[†] Lorenzo di Cesare Mannelli,[‡] Elena Trallori,[‡] Thomas S. Peat,[§] Carla Ghelardini,[‡] Fabrizio Carta,[†]⁶ and Claudiu T. Supuran^{*,†}⁶


[†]University of Florence, NEUROFARBA Dept., Sezione di Scienze Farmaceutiche, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Florence, Italy

[‡]NEUROFARBA Department, Section of Pharmacology and Toxicology, Università degli Studi di Firenze, Viale Pieraccini 6, 50139 Florence, Italy

[§]CSIRO, 343 Royal Parade, Parkville, Victoria 3052, Australia

Supporting Information

ABSTRACT: A series of novel selenides bearing benzenesulfonamide moieties was synthesized and investigated for their inhibition on six human (h) carbonic anhydrase (CA, EC 4.2.1.1) isoforms such as the physiologically relevant hCA I, II, VA, VB, VII, and IX and the X-ray complex in adduct with hCA II for some of them investigated. These enzymes are involved in a variety of diseases including glaucoma, retinitis pigmentosa, epilepsy, arthritis, metabolic disorders, and cancer. The investigated compounds showed potent inhibitory action against hCA VA, VII, and IX, in the low nanomolar range, thus making them of interest for the development of isoformselective inhibitors and as candidates for various biomedical applications.



KEYWORDS: Carbonic anhydrase inhibitors (CAIs), diabetic pathology, selenium, metalloenzymes, organoselenium

iabetes is a chronic disease, and the number of people in the world with the disease has risen from 108 million in 1980 to 422 million in 2014.¹ Several complications of diabetes associated with hyperglycemia lead to disrupt the microvasculature of insulin-insensitive tissues such as the eye, nerve, and brain.² These complications are caused by oxidative stress and lead to pericyte loss,^{3,4} disruption of the blood-brain barrier (BBB),^{5,6} and cognitive decline.⁷⁻⁹ The BBB is composed largely of endothelial cells in the microvasculature of the central nervous system. In close proximity to endothelial cells one finds cerebral pericytes, another type of cells vital for the integrity of the BBB.¹⁰ Pericyte cells are especially susceptible to oxidative stress, which leads to cell death by apoptosis.¹¹ One cause of oxidative stress is the overproduction of superoxide as a byproduct during excess respiration caused by produced influx of glucose in insulin sensitive tissues.² Mitochondrial human carbonic anhydrases hCA VA and VB (CAs, EC 4.2.1.1) play a central role in the metabolism of pyruvate, by sustaining the rate of respiration¹² as described in Figure 1.

Pyruvate is the end-product of the glycolytic pathway obtained by glucose in the cytosol. Pyruvate enters the mitochondria where it is carboxylated to oxaloacetate. In this step, the production of bicarbonate anion required for carboxylation is produced by mitochondrial hCAs through reversible reaction between water and carbon dioxide (CO₂ + $H_2O \Leftrightarrow HCO_3^- + H^+)$.¹⁷ Oxaloacetate, when entering the Krebs cycle, produces FADH₂ and NADH, which are carried out to the electron transfer chain (ETC) to generate ATP. O₂⁻ is a byproduct of ETC reactions, and it is the precursor of all ROS. The high activity of the Krebs cycle produces a high potential of mitochondrial membrane, which inhibits the transport of electrons to complex III, increasing the half-life of the free radicals of the coenzyme Q and reducing O_2 to O_2^{-} . Mitochondrial CA isoform VA was identified as one of the major contributors to brain diabetic disease;¹³ moreover, it was discover that hCAs IX and XII are recently implicated in ischemia-induced cerebrovascular pathology,¹⁴ making these enzymes attractive drug targets for obtaining agents that can interfere with these deleterious processes. This may lead to novel strategies to prevent diabetic complications in the brain and possibly in other insulin-insensitive tissues. Sulfonamides are the most widely investigated class of CAIs; among these, the most investigated are acetazolamide (AAZ), zonisamide (ZNS), and topiramate (TPM) as pharmacologic inhibitors of mitochondrial $hCAs^{15-17}$ as outlined in Figure 2.

Received: February 13, 2018 Accepted: April 9, 2018 Published: April 9, 2018




Figure 1. Mitochondrial CAs in ROS production and their role in brain pericytes apoptosis.






Figure 2. Structures of pharmacologic mitochondrial hCAs inhibitors: acetazolamide (AAZ), topiramate (TPM), and zonisamide (ZNS).

Topiramate, however, had several and serious side effects owing to its ability to inhibit other metabolic pathways,^{18,19} among which, there are nonmitochondrial CA,²⁰ and in many cases, it is not well tolerated by patients. Thus, it is essential to develop newer drugs with more selectivity and fewer side effects.

Compound Design and Synthesis. The drug design, in this study, starts with the idea to combine the sulfonamide moiety as a typical zinc binding group (ZBG) with the interesting antioxidant propriety of organo-selenium scaffolds.^{21–23} In the present study, we investigated different selenides incorporating a benzenesulfonamide moiety as a carbonic anhydrase inhibitor (CAI). The synthetic approach toward the synthesis of diselenide 3 is shown in Scheme 1. The






diazonium salt of sulfanilamide was prepared by reaction of 1 with sodium nitrite in the presence of acid (Sandmeyer reaction) and used as a key intermediate for the synthesis of compound 2. Successively, the selenocyanate derivative 2 was converted easily into the diselenide 3 as reported previously by our group²⁴ and outlined in Scheme 1.

Thereafter, **3** was reduced with NaBH₄ to the corresponding selenolate, which in turn was treated *in situ* with the appropriate halo-alkyl moieties 4a-j, affording the selenides 5a-j in good yields (Table 1).


Table 1. Synthesis of Selenides Bearing Benzenesulfonamide Moieties, 5a–j




^aYields refer to isolated products.


As a further investigation, in order to propose an alternative way to access the target compounds, we sought to achieve selenides from the selenocyanate 2, thus avoiding the synthesis of the diselenide 3. We were pleased to observe that selenides 5a-j were obtained by nucleophilic substitution with the


selenolate, *in situ* generated by reducing **2**, as reported in Scheme 2.






In order to access a different benzenesulfonamide with a seleno aromatic tail (9), the procedure started with synthesized 4-(bromomethyl)benzenesulfonamide 7 as reported in Scheme 3. Compound 7 was synthesized following the method of Naganawa et al.²⁵





Finally, the selenide 9 was obtained from the reduction of diphenyldiselenide 8 with $NaBH_4$ and was added *in situ* to sulfonamide 7 to afford in good yield the selenide 9 as outlined in Scheme 4.



Carbonic Anhydrase Inhibition. In this study was investigated the CA inhibition profile compounds 2, 3, 5a-j, and 9 against six human isoforms such as the physiologically relevant CA I, II, VA, VB, VII, and IX by means of the stopped-flow carbon dioxide hydration assay²⁶ after a period of 15 min of incubation of the enzyme and inhibitor solutions.^{27–31} Their activities were compared to the standard CAIs acetazolamide (AAZ) and topiramate (TPM) (Table 2).

One goal of this study was to generate compounds containing organoseleno scaffolds with antioxidant properties to improve selectivity of the targeting of mitochondrial hCA (VA and VB) compared with the clinically used topiramate inhibitor (**TPM**). For the preliminary investigation, we have tested the key intermediates **2** and **3**. We observed that the replacement of a selenocyanate group by a diselenide was well tolerated except for hCA I, so compound **3** displayed a constant of inhibition in the micromolar range ($K_i = 1522.7$ nM). The

Table 2. Inhibition Data of Human CA Isoforms I, II, IV, VA, VB, VII, and IX with Compounds 2, 3, 5a-j, 9, AAZ, and TPM by a Stopped Flow CO₂ Hydrase Assay²⁶

	$K_{i} (nM)^{a}$					
Compound	hCAI	hCA II	hCAVA	hCAVB	hCA VII	hCAIX
2	95.6	53.1	8.2	5.7	7.1	9.3
3	1522.7	7.9	7.3	5.7	40.5	2.7
5a	338.3	355.3	5.4	46.8	27.1	2.4
5b	256.8	9.3	5.1	36.0	0.31	8.7
5c	352.2	73.2	7.3	31.3	4.6	2.7
5d	9.7	69.9	7.1	5.7	0.28	2.4
Se	5.2	36.5	6.9	45.1	0.27	2.6
5f	7.3	9.3	5.8	22.8	0.25	2.7
Sg	293.5	7.6	7.1	16.8	2.0	2.2
5h	297.1	70.8	2.9	12.3	0.38	2.6
5i	21.9	6.3	8.8	12.7	0.24	2.6
Sj	261.7	41.2	4.0	5.5	0.77	12.0
9	226.1	53.0	5.4	19.1	6.6	2.7
AAZ	250	10	63	54	2.5	25.8
TPM	250	10	63	30	9.0	58

^{*a*}Mean from three different assays, by a stopped flow technique (errors were in the range of 5-10% of the reported values).

following structure-activity relationships (SARs) for selenides 5a-j and 9 were observed by analyzing CA inhibition profile in Table 2. The inhibition profile of hCA I was comparable to standards AAZ and TPM, except for 5d-f and 5i. These compounds showed an activity more than 10 times greater for 5i and over 25 times greater for 5d-f. The other dominant cytosolic isoform, hCA II, was inhibited by almost all selenides with an inhibition constant in the medium nanomolar range, except for compound **5a** in the high nanomolar range $(K_i = 6.3)$ to 355 nM). An interesting inhibition profile was observed for the mitochondrial isoform hCA VA. All compounds were potent inhibitors with an activity in the low nanomolar range $(K_i = 2.9 \text{ to } 8.8 \text{ nM})$. However, the small and cyclic moieties found in 5c, 5d, and 5i led to less active inhibitors. This potency was substantially higher than those for the reported standards; thus, these compounds were excellent candidates for follow-up cell-based studies. In addition, the second mitochondrial isoform hCA VB was also well inhibited by almost all selenides reported here. An interesting case was offered by compound 5a with 5j. The difference in structure is a hydroxyl group versus a methoxy moiety, respectively. However, compound 5a proved to be nearly 10-fold less potent than 5j. The last cytosolic human isoform here studied, hCA VII, was also strongly inhibited by selenides 5a-i with inhibition constants spanning from the subnanomolar ($K_i = 0.24$ nM) to the medium nanomolar range ($K_i = 27.4$ nM). Compound 5a, this time, showed a potency of inhibition 35-fold less than that of the compound incorporating the methoxyl tail (5j). The transmembrane isoform hCA IX was effectively inhibited by all compounds here reported with K_{is} in the range of 2.2–12 nM. The SAR is almost absent in this case, as all selenides showed a very comparable behavior as potent hCA IX inhibitors. In addition, hCA IX is not only implicated in ischemia-induced cerebrovascular pathology¹⁴ but its expression is upregulated in a wide type of hypoxic tumors. Thus, several of these compounds may have potential as anticancer therapeutics.

Complex of hCA II/Selenides Ligand Complex. The protein complex with compound **5e** was determinate by X-ray crystal structure, and we had obtained ligand-protein

interactions at the atomic level (Figure 3). hCA II was selected as a model isoform for crystallization because it easily forms




Figure 3. Whole protein hCA II with 5e bound (A) and active site region of the hCA II/5e complex (B) (PDB code: 6CEH).

crystals, and many studies have been reported on its structure with different classes of inhibitors.³²

Active site analysis of selenide 5e showed that the sulfonamide moiety of inhibitor was tightly coordinated to the Zn(II) ion by a binding mode to the protein similar to other CAIs containing the same ZBG.³² Additionally, hydrophobic residues that are in relatively close proximity of the inhibitor scaffold are shown around the alkyl chain of compound 5e (Figure 3b).

Biological Assays. Some selected compounds (3, 5a, 5d, 5h, and 5j), chosen among those possessing an interesting inhibitory profile against the mitochondrial hCA VA and VB, were tested to evaluate their effects on the viability of rat brain endothelial (RBE4) cells, cultured in oxidative stress conditions in the presence of glucose oxidase (GOx). First of all, we evaluated the cytotoxicity of the tested compounds against RBE4, and the cell viability is shown in Figure 4.




Figure 4. RBE4 cell viability $(4 \times 10^4 \text{ cell/well})$ following 24 h incubation with compounds **3**, **5a**, **5d**, **5h**, and **5j** at 10, 30, and 100 μ M. *p < 0.001 versus control.

Diselenide 3 was significantly cytotoxic, inducing a mortality of about 50% at a concentration of 30 μ M. All other selenides here reported proved to be safe at low concentrations. One should note that a decrease of cell viability was measured at high concentrations (100 μ M), after 24 h treatment with compounds **5a** and **5h**. The safe compounds **5a**, **5d**, **5h**, and **5j** were evaluated as possible scavengers of oxidative stress by GOx. RBE4 cells were incubated with glucose oxidase in two

GOx 0.1 U/ml 140 120 100 Cell viability (%) 80 **5**d 60 ≡ 5h 40 **5** 20 Topiramate 0 control 100 µM 30 uM 10 uM Concentration (M) GOx 0.3 U/ml 140 120 100 Cell viability (%) control 80 **5**a **5**d 60 ■ 5h 40 **5** 20 Topiramate 0 control 10 µM 30 µM 100 µM Concentration (M)

concentrations (0.1 and 0.3 U/mL) and selenides, and the

results are shown in Figure 5.

Figure 5. RBE4 cells (4 × 10⁴ cell/well) were incubated 1 h with GOx (0.1, 0.3 U/mL) and **5a**, **5d**, **5h**, and **5j** (10 and 30 μ M, also 100 μ M, when it was not cytotoxic), and the following 24 h, they recovered in culture medium with the compounds at the same concentrations. ***p* < 0.01, ****p* < 0.001 versus control; ^*p* < 0.05 vs GOX 0.1 U/mL.

Cell viability of control decreases up to 40% with enhancement of GOx. Among the tested compounds, only selenide **5j** showed good protection of cerebral endothelial cells from GOx damage at the higher dose (100 μ M). The other selenides did not show any significant scavenger activity in these assay conditions.

Conclusion. We have designed, synthesized, and obtained an X-ray crystallographic structure of a novel series of selenides bearing the benzenesulfonamide moieties, which behave as potent mitochondrial CA inhibitors. Compound **5j** proved to be effective as a scavenger agent on RBE4 cell line. Selective binding to mitochondrial CA is an important undertaking for targeting diabetic cerebrovascular pathology and is challenging with classical pharmacologically using sulfonamide/sulfamate CA inhibitors. The findings reported here are of substantial interest and highlight the potential of selenides bearing benzenesulfonamide groups to be exploited for the discovery of potent, mitochondrial-selective CA inhibitors. Thus, in the future we will design new selenides with more selectivity and protector attributes for viability of rat brain endothelial (RBE4) cells.

D

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsmedchem-lett.8b00076.

Synthetic procedures, characterization of compounds, in vitro kinetic procedure, X-ray crystallography, and biological assay (PDF)

AUTHOR INFORMATION

Corresponding Author

*Tel/Fax: +39-055-4573729. E-mail: claudiu.supuran@unifi.it. ORCID ©

Fabrizio Carta: 0000-0002-1141-6146

Claudiu T. Supuran: 0000-0003-4262-0323

Author Contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank the Australian Synchrotron and the beamline scientists for their help with data collection and thank OpenEye Scientific Software for a license to the program Afitt. The C3 Crystallisation Centre (crystal.csiro.au) is acknowledged for all crystallization experiments.

ABBREVIATIONS

BBB, blood-brain barrier; CAs, carbonic anhydrases; ZBG, zinc binding group; AAZ, acetazolamide; ZNS, zonisamide; TPM, topiramate; RBE4, rat brain endothelial cell; GOx, glucose oxidase; ETC, electron transfer chain

REFERENCES

(1) Mathers, C. D.; Loncar, D. Projection of global mortality and burden of disease from 2002 to 2030. *PLoS Med.* **2006**, *3*, e442.

(2) Balasubramanyam, M.; Rema, M.; Premanand, C. Biochemical and molecular mechanisms of diabetic retinopathy. *Curr. Sci.* 2002, *83*, 1506–1514.

(3) Price, T. O.; Eranki, V.; Banks, W. A.; Ercal, N.; Shah, G. N. Topiramate treatment protects blood-brain barrier pericytes from hyperglycemia-induced oxidative damage in diabetic mice. *Endocrinology* **2012**, *153*, 362–372.

(4) Price, T. O.; Farr, S. A.; Niehoff, M. L.; Ercal, N.; Morley, J. E.; Shah, G. N. Protective effect of topiramate on hyperglycemia-induced cerebral oxidative stress, pericyte loss and learning behavior in diabetic mice. *Int. Libr. Diabetes Metab.* **2015**, *1*, 6–12.

(5) Starr, J. M.; Wardlaw, J.; Ferguson, K.; MacLullich, A.; Deary, I. J.; Marshall, I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. *J. Neurol., Neurosurg. Psychiatry* **2003**, *74*, 70–76.

(6) Woerdeman, J.; Van Duinkerken, E.; Wattjes, M. P.; Barkhof, F.; Snoek, F. J.; Moll, A. C.; Klein, M.; de Boer, M. P.; Ijzerman, R. G.; Serne, E. H.; Diamant, M. Proliferative retinopathy in type 1 diabetes is associated with cerebral microbleeds, which is part of generalized microangiopathy. *Diabetes Care* **2014**, *37*, 1165–1168.

(7) Huber, J. D. Diabetes, cognitive function, and the blood-brain barrier. *Curr. Pharm. Des.* **2008**, *14*, 1594–1600.

(8) Janson, J.; Laedtke, T.; Parisi, J. E.; O'Brien, P.; Petersen, R. C.; Butler, P. C. Increased risk of type 2 diabetes in Alzheimer disease. *Diabetes* **2004**, *53*, 474–481. (9) Kalaria, R. N. Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer disease. *Nat. Rev. Neurol.* **2009**, *5*, 305–306. (10) Armulik, A.; Genove, G.; Mae, M.; Nisancioglu, M. H.; Wallgard, E.; Niaudet, C.; He, L.; Norlin, J.; Lindblom, P.; Strittmatter, K.; Johansson, B. R.; Betsholtz, C. Pericytes regulate the blood-brain barrier. *Nature* **2010**, *468*, 557–561.

(11) Shah, G. N.; Price, T. O.; Banks, W. A.; Morofuji, Y.; Kovac, A.; Ercal, N.; Sorenson, C. M.; Shin, E. S.; Sheibani, N. Pharmacological inhibition of mitochondrial carbonic anhydrases protects mouse cerebral pericytes from high glucose-induced oxidative stress and apoptosis. J. Pharmacol. Exp. Ther. **2013**, 344, 637–645.

(12) Price, T. O.; Sheibani, N.; Shah, G. N. Regulation of high glucose-induced apoptosis of brain pericytes by mitochondrial CA VA: A specific target for prevention of diabetic cerebrovascular pathology. *Biochim. Biophys. Acta, Mol. Basis Dis.* **2017**, *4*, 929–935.

(13) Patrick, P.; Price, T. O.; Diogo, A. L.; Sheibani, N.; Banks, W. A.; Shah, G. N. Topiramate Protects Pericytes from Glucotoxicity: Role for Mitochondrial CA VA in Cerebromicrovascular Disease in Diabetes. *J. Endocrinol Diabetes* **2015**, *2*, 1–7.

(14) Di Cesare Mannelli, L.; Micheli, L.; Carta, F.; Cozzi, A.; Ghelardini, C.; Supuran, C. T. Carbonic anhydrase inhibition for the management of cerebral ischemia: in vivo evaluation of sulfonamide and coumarin inhibitors. *J. Enzyme Inhib. Med. Chem.* **2016**, *31*, 894–899.

(15) De Simone, G.; Supuran, C. T. Antiobesity carbonic anhydrase inhibitors. *Curr. Top. Med. Chem.* **2007**, *7*, 879.

(16) Poulsen, S. A.; Wilkinson, B. L.; Innocenti, A.; Vullo, D.; Supuran, C. T. Inhibition of human mitochondrial carbonic anhydrases VA and VB with para-(4-phenyltriazole-1-yl)-benzenesulfonamide derivatives. *Bioorg. Med. Chem. Lett.* **2008**, *18*, 4624.

(17) Supuran, C. T. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nat. Rev. Drug Discovery* **2008**, *7*, 168.

(18) Shah, G. N.; Rubbelke, T. S.; Hendin, J.; Nguyen, H.; Waheed, A.; Shoemaker, J. D. Targeted mutagenesis of mitochondrial carbonic anhydrases VA and VB implicates both enzymes in ammonia detoxification and glucose metabolism. *Proc. Natl. Acad. Sci. U. S. A.* **2013**, *110*, 7423–7428.

(19) Deutsch, S. I.; Schwartz, B. L.; Rosse, R. B.; Mastropaolo, J.; Marvel, C. L.; Drapalski, A. L. Adjuvant topiramate administration: a pharmacologic strategy for addressing NMDA receptor hypofunction in schizophrenia. *Clin. Neuropharmacol.* **2003**, *26*, 199–206.

(20) Nishimori, I.; Vullo, D.; Innocenti, A.; Scozzafava, A.; Mastrolorenzo, A.; Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of the transmembrane isozyme XIV with sulfonamides. *Bioorg. Med. Chem. Lett.* **2005**, *17*, 3828–3833.

(21) Angeli, A.; Tanini, D.; Peat, T. S.; Di Cesare Mannelli, L.; Bartolucci, G.; Capperucci, A.; Ghelardini, C.; Supuran, C. T.; Carta, F. Discovery of New Selenoureido Analogues of 4-(4-Fluorophenylureido)benzenesulfonamide as Carbonic Anhydrase Inhibitors. ACS Med. Chem. Lett. 2017, 8, 963-968.

(22) Tanini, D.; Panzella, L.; Amorati, R.; Capperucci, A.; Pizzo, E.; Napolitano, A.; Menichetti, S.; d'Ischia, M. Resveratrol-based benzoselenophenes with an enhanced antioxidant and chain breaking capacity. *Org. Biomol. Chem.* **2015**, *13*, 5757–5764.

(23) Angeli, A.; Tanini, D.; Viglianisi, C.; Panzella, L.; Capperucci, A.; Menichetti, S.; Supuran, C. T. Evaluation of selenide, diselenide and selenoheterocycle derivatives as carbonic anhydrase I, II, IV, VII and IX inhibitors. *Bioorg. Med. Chem.* **2017**, *25*, 2518–2523.

(24) Angeli, A.; Tanini, D.; Capperucci, A.; Supuran, C. T. Synthesis of novel selenides bearing benzenesulfonamide moieties as carbonic anhydrase I, II, IV, VII and IX inhibitors. *ACS Med. Chem. Lett.* **2017**, *8*, 1213–1217.

(25) Naganawa, A.; Matsui, T.; Ima, M.; Saito, T.; Murota, M.; Aratani, Y.; Kijima, H.; Yamamoto, H.; Maruyama, T.; Ohuchida, S.; Nakai, H.; Toda, M. Further optimization of sulfonamide analogs as EP1 receptor antagonists: Synthesis and evaluation of bioisosteres for the carboxylic acid group. *Bioorg. Med. Chem.* **2006**, *14*, 7121–7137. (26) Khalifah, R. G. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop flow kinetic studies on the native human isoenzymes B and C. J. Biol. Chem. **1971**, 246, 2561.

(27) Annunziato, G.; Angeli, A.; D'Alba, F.; Bruno, A.; Pieroni, M.; Vullo, D.; De Luca, V.; Capasso, C.; Supuran, C. T.; Costantino, G. Discovery of New Potential Anti-Infective Compounds Based on Carbonic Anhydrase Inhibitors by Rational Target-Focused Repurposing Approaches. *ChemMedChem* **2016**, *11*, 1904–1914.

(28) Angeli, A.; Carta, F.; Bartolucci, G.; Supuran, C. T. Synthesis of novel acyl selenoureido benzensulfonamides as carbonic anhydrase I, II, VII and IX inhibitors. *Bioorg. Med. Chem.* **2017**, *25*, 3567.

(29) Angeli, A.; Peat, T. S.; Bartolucci, G.; Nocentini, A.; Supuran, C. T.; Carta, F. Intramolecular oxidative deselenization of acylselenoureas: a facile synthesis of benzoxazole amides and carbonic anhydrase inhibitors. *Org. Biomol. Chem.* **2016**, *14*, 11353–11356.

(30) Mishra, C. B.; Kumari, S.; Angeli, A.; Monti, S. M.; Buonanno, M.; Tiwari, M.; Supuran, C. T. Discovery of Benzenesulfonamides with Potent Human Carbonic Anhydrase Inhibitory and Effective Anticonvulsant Action: Design, Synthesis, and Pharmacological Assessment. J. Med. Chem. 2017, 60, 2456–2469.

(31) Angeli, A.; Abbas, G.; Del Prete, S.; Carta, F.; Capasso, C.; Supuran, C. T. Acyl selenoureido benzensulfonamides show potent inhibitory activity against carbonic anhydrases from the pathogenic bacterium Vibrio cholerae. *Bioorg. Chem.* **2017**, *75*, 170–172.

(32) Alterio, V.; Di Fiore, A.; D'Ambrosio, K.; Supuran, C. T.; De Simone, G. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? *Chem. Rev.* **2012**, *112*, 4421–4468.